Peripheral primitive neuroectodermal tumors (pPNETs) are small embryonic carcinomas that develop in the soft tissue and bone, away from the central nervous system (CNS) and sympathetic nervous system ...
The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...
After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine tumors. The small-molecule drug is now allowed for patients 12 years of age and older ...
The latest update is out from Perspective Therapeutics ( (CATX) ).
Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will have to first face the agency’s Oncologic Drugs Advisory Committee (ODAC) in ...
The study, published in British scientific journal Nature, suggests that the disease may begin in basal stem cells — ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback